Regeneron

News
Regeneron launches $500m venture capital arm

Regeneron launches $500m venture capital arm

Regeneron has formed a corporate venture capital unit with $100 million a year to invest over the next five years in “biopharmaceutical, healthcare, and health technology”

News
FDA will decide in June on Dupixent for COPD

FDA will decide in June on Dupixent for COPD

The FDA has started a priority review of Sanofi and Regeneron’s Dupixent as a treatment for chronic obstructive pulmonary disease (COPD), which could become the first new